Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Clinical Trial of the STING Agonist CRD3874-SI in Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT06626633 is registered in ClinicalTrials.gov with University of Maryland, Baltimore as lead sponsor.

NCT NCT06626633
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06626633 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Clinical Trial of the STING Agonist CRD3874-SI in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Lead sponsor
University of Maryland, Baltimore
Phase
Phase 1
Overall status
Suspended
Start date
August 26, 2024
Completion date
January 31, 2028
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia